Literature DB >> 9384239

The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells.

C Rundfeldt1.   

Abstract

The patch-clamp technique was used to measure currents passing through K+ channels in neuronal cell preparations. Retigabine (D-23129, N-(2-amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid ethyl ester) activated a K+ conductance in slightly depolarized NG108-15 neuronal cells in a dose-dependent manner (0.1-10 microM). At the K+ reversal potential, no current could be elicited and in hyperpolarized cells the current was reversed. A similar current was elicited in primary cultures of mouse cortical neurones and in differentiated hNT cells, a cell line derived from human neuronal cells. At higher concentrations, retigabine also partially blocked voltage activated K+ currents. None of the tested anticonvulsants, phenytoin, carbamazepine and valproate and none of the K+ channel openers cromakalim, diazoxide and pinacidil exerted a similar effect. The current was not affected by the K+ channel blocker glibenclamide (10 microM) but was fully blocked by application of Ba2+ (10.8 mM). Exchange of K+ with cesium in the intracellular space also fully abolished the current. It can be expected that the K+ channel opening effect contributes to the anticonvulsant activity of retigabine.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9384239     DOI: 10.1016/s0014-2999(97)01249-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  52 in total

1.  Discovery, Synthesis, and Structure Activity Relationship of a Series of N-Aryl- bicyclo[2.2.1]heptane-2-carboxamides: Characterization of ML213 as a Novel KCNQ2 and KCNQ4 Potassium Channel Opener.

Authors:  Haibo Yu; Meng Wu; Steven D Townsend; Beiyan Zou; Shunyou Long; J Scott Daniels; Owen B McManus; Min Li; Craig W Lindsley; Corey R Hopkins
Journal:  ACS Chem Neurosci       Date:  2011-10-19       Impact factor: 4.418

2.  The pharmacology of new antiepileptic drugs: does a novel mechanism of action really matter?

Authors:  Emilio Perucca
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

3.  Ezogabine (retigabine).

Authors:  Carl E Stafstrom; Seden Grippon; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2011-09-30       Impact factor: 84.694

Review 4.  Diverse mechanisms of antiepileptic drugs in the development pipeline.

Authors:  Michael A Rogawski
Journal:  Epilepsy Res       Date:  2006-04-18       Impact factor: 3.045

5.  Effects of retigabine on the neurodegeneration and extracellular glutamate changes induced by 4-aminopyridine in rat hippocampus in vivo.

Authors:  Gabriela Mora; Ricardo Tapia
Journal:  Neurochem Res       Date:  2005-12       Impact factor: 3.996

6.  egl-4 modulates electroconvulsive seizure duration in C. elegans.

Authors:  Monica G Risley; Stephanie P Kelly; Justin Minnerly; Kailiang Jia; Ken Dawson-Scully
Journal:  Invert Neurosci       Date:  2018-05-30

7.  Participation of KCNQ (Kv7) potassium channels in myogenic control of cerebral arterial diameter.

Authors:  Xi Zoë Zhong; Maksym I Harhun; Soren P Olesen; Susumu Ohya; James D Moffatt; William C Cole; Iain A Greenwood
Journal:  J Physiol       Date:  2010-07-12       Impact factor: 5.182

8.  Comparison of the long-term behavioral effects of neonatal exposure to retigabine or phenobarbital in rats.

Authors:  Sari Frankel; Natalia Medvedeva; Samuel Gutherz; Catherine Kulick; Alexei Kondratyev; Patrick A Forcelli
Journal:  Epilepsy Behav       Date:  2016-02-24       Impact factor: 2.937

Review 9.  One man's side effect is another man's therapeutic opportunity: targeting Kv7 channels in smooth muscle disorders.

Authors:  T A Jepps; S P Olesen; I A Greenwood
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

10.  Combinatorial augmentation of voltage-gated KCNQ potassium channels by chemical openers.

Authors:  Qiaojie Xiong; Haiyan Sun; Yangming Zhang; Fajun Nan; Min Li
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.